Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943785 | 0.88 | TSHR (0.51) | TRPV4TSHRHSD17B10TRPM4RXFP1 | |
| SCHEMBL5649740 | 0.86 | TRPV4 (0.57) | TRPV4TSHRTRPM4KDM4ERXFP1 | |
| SCHEMBL1546502 | 0.85 | TDP1 (0.58) | TRPV4TSHRKDM4ERXFP1CYP3A4 | |
| SCHEMBL1614434 | 0.82 | ALDH1A1 (0.57) | HSD17B10TRPM4KDM4EXDHSLC22A12 | |
| SCHEMBL7896006 | 0.79 | TSHR (0.45) | TSHRHSD17B10KDM4ECYP3A4LMNA | |
| SCHEMBL18528829 | 0.79 | PTGDR2 (0.60) | TRPV4PTGDR2ALDH1A1MAPT | |
| SCHEMBL4844621 | 0.78 | KDM4E (0.70) | TSHRHSD17B10KDM4ECYP3A4LMNA | |
| SCHEMBL2769244 | 0.78 | ADRB1 (0.55) | TSHRHSD17B10KDM4ECYP3A4LMNA | |
| SCHEMBL17293972 | 0.78 | ALDH1A1 (0.50) | KDM4EXDHSLC22A12ALDH1A1 | |
| SCHEMBL1402437 | 0.78 | TRPV4 (0.61) | TRPV4HSD17B10KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925322-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9777002-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150299198-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2925322-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-1960368-B1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014085210-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-2311814-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7851626-B2 | 4,4,5,5, tetrasubstituted imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2130822-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| US-7579368-B2 | Cis-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| EP-1187813-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
| WO-2001000587-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | TRPV4 2479/4885TSHR 161/4885HSD17B10 1551/4885 |
| US-20150299198-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | TRPV4 245/4885TSHR 1548/4885HSD17B10 3184/4885 |
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | TRPV4 3975/4885TSHR 2239/4885HSD17B10 3572/4885 |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | TRPV4 2947/4885TSHR 1158/4885HSD17B10 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.